RGEN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,912.02 -- higher than 98.56% of US-listed equities with positive expected earnings growth.
With a price/earnings ratio of 289.79, Repligen Corp P/E ratio is greater than that of about 97.52% of stocks in our set with positive earnings.
The price/operating cash flow metric for Repligen Corp is higher than 97.23% of stocks in our set with a positive cash flow.
Stocks with similar financial metrics, market capitalization, and price volatility to Repligen Corp are TDOC, MLAB, PRAH, AKAM, and PAYC.
Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
RGEN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Repligen Corp. To summarize, we found that Repligen Corp ranked in the 12th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 89%. The most interesting components of our discounted cash flow analysis for Repligen Corp ended up being:
In the past 5.38 years, Repligen Corp has a compound free cash flow growth rate of 0.25%; that's higher than 61.67% of free cash flow generating stocks in the Healthcare sector.
97% of the company's capital comes from equity, which is greater than 89.47% of stocks in our cash flow based forecasting set.
The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 10.5% of the free cash flow producing stocks we're observing.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RGEN, try BLFS, ELAN, LGND, PCRX, and TEVA.
Repligen Corporation (RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Financial Corp. Puneet Souda -...
* Reports record quarterly revenue of $87.5 million * Overall revenue grew 24% year-over-year, with organic growth of 19% * Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth * Completes acquisition of silicone molding and tubing manufacturer Engineered Molding TechnologyWALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call.Tony J. H...